Literature DB >> 22005476

Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.

Sanjay Popat1, Alexandra Vieira de Araújo, Toon Min, John Swansbury, Melissa Dainton, Andrew Wotherspoon, Eric Lim, Andrew G Nicholson, Mary E R O'Brien.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22005476     DOI： 10.1097/JTO.0b013e31822eec5e

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  31 in total

Review 1.  ALK alterations and inhibition in lung cancer.

Authors:  Tri Le; David E Gerber
Journal:  Semin Cancer Biol       Date:  2016-09-13       Impact factor: 15.707

2.  Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.

Authors:  Yiming Zhao; Shuyuan Wang; Bo Zhang; Rong Qiao; Jianlin Xu; Lele Zhang; Yanwei Zhang; Baohui Han
Journal:  Target Oncol       Date:  2019-04       Impact factor: 4.493

Review 3.  Treating ALK-positive lung cancer--early successes and future challenges.

Authors:  D Ross Camidge; Robert C Doebele
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

Review 4.  Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.

Authors:  Eunhee S Yi; Jin-Haeng Chung; Kimary Kulig; Keith M Kerr
Journal:  Mol Diagn Ther       Date:  2012-06-01       Impact factor: 4.074

Review 5.  Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

Authors:  Sai-Hong Ignatius Ou; Cynthia Huang Bartlett; Mari Mino-Kenudson; Jean Cui; A John Iafrate
Journal:  Oncologist       Date:  2012-09-18

6.  ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.

Authors:  Justin F Gainor; Anna M Varghese; Sai-Hong Ignatius Ou; Sheheryar Kabraji; Mark M Awad; Ryohei Katayama; Amanda Pawlak; Mari Mino-Kenudson; Beow Y Yeap; Gregory J Riely; A John Iafrate; Maria E Arcila; Marc Ladanyi; Jeffrey A Engelman; Dora Dias-Santagata; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2013-05-31       Impact factor: 12.531

7.  Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer.

Authors:  Lin Yang; Guangchao Li; Likun Zhao; Fei Pan; Jiankun Qiang; Siqi Han
Journal:  Tumour Biol       Date:  2014-06-29

8.  Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma.

Authors:  Jianfei Zhu; Ling Cai; Haoxian Yang; Yinsheng Wen; Junye Wang; Tiehua Rong; Jianyong Shao; Lanjun Zhang
Journal:  Thorac Cancer       Date:  2014-08-25       Impact factor: 3.500

9.  Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation.

Authors:  Akihiko Miyanaga; Kumi Shimizu; Rintaro Noro; Masahiro Seike; Kazuhiro Kitamura; Seiji Kosaihira; Yuji Minegishi; Takehito Shukuya; Akinobu Yoshimura; Masashi Kawamoto; Shinichi Tsuchiya; Koichi Hagiwara; Manabu Soda; Kengo Takeuchi; Nobuyuki Yamamoto; Hiroyuki Mano; Yuichi Ishikawa; Akihiko Gemma
Journal:  BMC Cancer       Date:  2013-05-29       Impact factor: 4.430

10.  A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.

Authors:  Hisashi Tanaka; Akihito Hayashi; Takeshi Morimoto; Kageaki Taima; Yoshihito Tanaka; Michiko Shimada; Akira Kurose; Shingo Takanashi; Ken Okumura
Journal:  BMC Cancer       Date:  2012-11-26       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.